{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Neuhann F"],"funding":["Hector Stiftung, Weinheim , Germany"],"pagination":["22"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7240935"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Background</h4>Pre-treatment drug resistance (PDR) among antiretroviral drug-naïve people living with HIV (PLHIV) represents an important indicator for the risk of treatment failure and the spread of drug resistant HIV variants. We assessed the prevalence of PDR and treatment outcomes among adults living with HIV-1 in Lilongwe, Malawi.<h4>Methods</h4>We selected 200 participants at random from the Lighthouse Tenofovir Cohort Study (LighTen). Serum samples were drawn prior to treatment initiation in 2014 and 2015, frozen, and later analyzed for the presence of HIV-1 drug resistance mutations. Amplicons were sequenced and interpreted by Stanford HIVdb interpretation algorithm 8.4. We assessed treatment outcomes by evaluating clinical outcome and viral suppression at the end of the follow"],"journal":["AIDS research and therapy"],"pubmed_title":["Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi."],"pmcid":["PMC7240935"],"funding_grant_id":["M72"],"pubmed_authors":["Neuhann F","Tweya H","Fatkenheuer G","Heger E","Nhlema A","Kaiser R","de Forest A","Steffen HM","Phiri S","Scheller C"],"additional_accession":[]},"is_claimable":false,"name":"Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi.","description":"<h4>Background</h4>Pre-treatment drug resistance (PDR) among antiretroviral drug-naïve people living with HIV (PLHIV) represents an important indicator for the risk of treatment failure and the spread of drug resistant HIV variants. We assessed the prevalence of PDR and treatment outcomes among adults living with HIV-1 in Lilongwe, Malawi.<h4>Methods</h4>We selected 200 participants at random from the Lighthouse Tenofovir Cohort Study (LighTen). Serum samples were drawn prior to treatment initiation in 2014 and 2015, frozen, and later analyzed for the presence of HIV-1 drug resistance mutations. Amplicons were sequenced and interpreted by Stanford HIVdb interpretation algorithm 8.4. We assessed treatment outcomes by evaluating clinical outcome and viral suppression at the end of the follow","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2025-04-05T09:50:49.491Z","creation":"2020-06-02T07:12:20Z"},"accession":"S-EPMC7240935","cross_references":{"pubmed":["32434561"],"doi":["10.1186/s12981-020-00282-3"]}}